Multiple sclerosis (MS) is a chronic, degenerative disease of the central nervous system (CNS) that is characterized by inflammation, demyelination, glial healing, and axonal degeneration. Its etiology is unknown, but it is believed to be an autoimmune inflammatory process that is triggered in patients with a genetic predisposition and exposed to certain environmental factors, both of which are unknown. Activation of B and T lymphocytes and glia macrophages would be responsible for demyelination and axonal degeneration. MS affects about 2.3 million people worldwide, with a higher prevalence in high-latitude countries. According to data from the Multiple Sclerosis Federation, the prevalence in Spain is estimated at around 120 cases per 100,000 inhabitants, with an incidence of 4 cases per 100,000 inhabitants per year. It is usually diagnosed between the ages of 20 and 40 and is more common in women than in men (two thirds of patients are women) .
Siponimod; S1P receptor modulator; Progressive secondary multiple sclerosis
Programa d'Harmonització Farmacoterapèutica. Siponimod per al tractament de l’esclerosi múltiple secundària progressiva. Barcelona: Servei Català de la Salut; 2021.
Use this identifier for quote and/or link this documenthttp://hdl.handle.net/11351/6412
This item appears in following collections
The following license files are associated with this item: